Physician profile
David C Rishikof
NPI 1750360657
$1,422.81
in general payments reported to CMS, 2019-2025
16 companies · $53.08 in 2025
The $53.08 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $20.69 · 2021: $956 · 2022: $16.78 · 2023: $58.69 · 2025: $53.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $843.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $192.49 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $64.26 | 2019-2023 | Nucala |
| Pacira Therapeutics, INC. | $45.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.90 | 2019-2020 | |
| Lilly USA, LLC | $35.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.06 | 2019 | |
| Eisai INC. | $21.03 | 2019 | |
| Genzyme Corporation | $20.25 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $18.93 | 2019 | |
| Amgen INC. | $18.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.72 | 2019 | |
| Exelixis INC. | $13.09 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rishikof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.